Advances in therapeutic strategies for primary CNS B-cell lymphomas

References

• Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology. 2017;2017:556–564.
   PubMedGoogle Scholar
• Rubenstein JL, Gupta NK, Mannis GN, et al. How I treat CNS lymphomas. Blood. 2013;122:2318–2330.
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16:859–863.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512–1520.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–e227.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal L. Lancet Haematol. 2017;4:e510–e523.
   PubMed Web of Science ®Google Scholar
• Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730–4735.
   PubMed Web of Science ®Google Scholar
• Correa DD, Rocco-Donovan M, DeAngelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol. 2009;91:315–321.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MGM, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869–881.
   PubMed Web of Science ®Google Scholar
• Dewitt JC, Mock A, Louis DN. The 2016 WHO classification of central nervous system tumors: what neurologists need to know. Curr Opin Neurol. 2017;30:643–649.
   PubMedGoogle Scholar
• Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105:1414–1418.
   PubMed Web of Science ®Google Scholar
• Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection. Handb Clin Neurol. 2018;152:177–186.
   PubMedGoogle Scholar
• Citterio G, Reni M, Gatta G, et al. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017;113:97–110.
   PubMed Web of Science ®Google Scholar
• Evens AM, Choquet S, Kroll-Desrosiers AR, et al. Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013;13:1512–1522.
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Batchelor TT. Primary central nervous system lymphoma: overview of current treatment strategies. Hematol Oncol Clin North Am. 2012;26:897–916.
   PubMedGoogle Scholar
• Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol. 2013;9:317–327.
   PubMed Web of Science ®Google Scholar
• Heald AE, Hoffman JM, Bartlett JA, et al. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS. 1996;7:337–346.
   PubMedGoogle Scholar
• Da Rocha AJ, Sobreia Guedes B V, da Silveira da Rocha TMB, et al. Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis. Rev Bras Hematol Hemoter. 2016;38:44–54.
   PubMedGoogle Scholar
• Lim WH, Russ GR, Coates PTH. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology. 2006;11:355–366.
   PubMed Web of Science ®Google Scholar
• Deckert M, Engert A, Brück W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25:1797–1807.
   PubMed Web of Science ®Google Scholar
• Brunn A, Nagel I, Montesinos-Rongen M, et al. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC lowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathol. 2013;126:603–605.
   PubMedGoogle Scholar
• Dandachi D, Ostrom QT, Chong I, et al. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. Cancer Causes Control. 2019;30:477–488.
   PubMedGoogle Scholar
• King RL, Goodlad JR, Calaminici M, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020;476:647–665.
   PubMed Web of Science ®Google Scholar
• Deckert M, Montesinos-Rongen M, Brunn A, et al. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol. 2014;127:175–188.
   PubMedGoogle Scholar
• Knittel G, Liedgens P, Korovkina D, et al. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Blood. 2016;127:2732–2741.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Schmitz R, Brunn A, et al. Mutations of CARD11 but not TNFAIP3 may activate the NF-κB pathway in primary CNS lymphoma. Acta Neuropathol. 2010;120:529–535.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107:3716–3723.
   PubMed Web of Science ®Google Scholar
• Fischer L, Hummel M, Korfel A, et al. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol. 2011;13:1090–1098.
   PubMedGoogle Scholar
• Braggio E, Van Wier S, Ojha J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21:3986–3994.
   PubMed Web of Science ®Google Scholar
• Schwindt H, Vater I, Kreuz M, et al. Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia. 2009;23:1875–1884.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent Mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18:5203–5211.
   PubMed Web of Science ®Google Scholar
• Braggio E, McPhail ER, Macon W, et al. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res. 2011;17:4245–4253.
   PubMed Web of Science ®Google Scholar
• Fischer L, Korfel A, Pfeiffer S, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15:5968–5973.
   PubMed Web of Science ®Google Scholar
• Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9–17.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90:353–358.
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O’Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21:1044–1049.
   PubMed Web of Science ®Google Scholar
• Gerstner ER, Carson KA, Grossman SA, et al. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008;70:401–402.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Küker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Annals of Neurology. 2005;57(6):843–847.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3:e388–e397.
   PubMed Web of Science ®Google Scholar
• Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125:1403–1410.
   PubMed Web of Science ®Google Scholar
• Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019;37:823–833.
   PubMed Web of Science ®Google Scholar
• Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20:216–228.
   PubMed Web of Science ®Google Scholar
• Yu J, Du H, Ye X, et al. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Sci Rep. 2021;11(1):2125.
   PubMedGoogle Scholar
• Joerger M, Huitema ADR, Krähenbühl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102:673–677.
   PubMed Web of Science ®Google Scholar
• Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2:e251–e259.
   PubMed Web of Science ®Google Scholar
• Illerhaus G, Marks R, Müller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319–325.
   PubMed Web of Science ®Google Scholar
• Kasenda B, Ferreri AJM, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis. Ann Oncol. 2015 Internet;26:1305–1313.
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31:846–852.
   PubMed Web of Science ®Google Scholar
• Olivier G, Gardembas M, Delwail V, et al. Phase I/II study of escalating doses of idarubicin in combination with methotrexate, vindesine and prednisolone in patients with primary central nervous system lymphoma: results of the GOELAMS LCP99 multicenter trial. Blood. 2009 Internet;114:2694.
   Google Scholar
• Pulczynski EJ, Kuittinen O, Erlanson M, et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the nordic lymphoma group. Haematologica. 2015;100:534–540.
   PubMed Web of Science ®Google Scholar
• Kurzwelly D, Glas M, Roth P, et al. Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol. 2010;97:389–392.
   PubMed Web of Science ®Google Scholar
• Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007;96(6):864–867.
   PubMed Web of Science ®Google Scholar
• Nayak L, Abrey LE, Drappatz J, et al. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013;54(1):58–61.
   PubMed Web of Science ®Google Scholar
• Wieduwilt MJ, Valles F, Issa S, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18:1146–1155.
   PubMed Web of Science ®Google Scholar
• Birsen R, Blanc E, Burroni B, et al. Efficacy and safety of intensive etoposide aracytine consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma. Blood. 2017;103(7):e296–e299.
   Google Scholar
• Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061–3068.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–926.
   PubMed Web of Science ®Google Scholar
• Aw A, Brown JR. Current status of bruton’s tyrosine kinase inhibitordevelopment and use in b-cell malignancies. Drugs Aging. 2017;34:509–527.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42:279–290.
   PubMed Web of Science ®Google Scholar
• Wang YL. MYD88 Mutations and Sensitivity to Ibrutinib Therapy. J Mol Diagnostics. 2018;20:264–266.
   PubMedGoogle Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018–1029.
   PubMed Web of Science ®Google Scholar
• Choquet S, Houillier C, Bijou F, et al. ibrutinib monotherapy in relapse or refractory primary cns lymphoma (PCNSL) and primary vitreo-retinal lymphoma (pvrl). result of the interim analysis of the iLOC phase II study from the lysa and the french LOC network. Blood. 2016;128:784.
   Google Scholar
• Simard J, Melani C, Lakhotia R, et al. Preliminary results of a response-adapted study of ibrutinib and isavuconazole with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDI-R) for secondary CNS lymphoma. Blood. 2020 Internet;136:24–25.
   PubMed Web of Science ®Google Scholar
• Renaud L, Bossard J-B, Terriou L, et al. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Eur J Haematol.2021;107(1):370–373. Internet.
   PubMedGoogle Scholar
• Yang Y, Shaffer AL, Emre NCT, et al. exploiting synthetic lethality for the therapy of ABC diffuse large b cell lymphoma. Cancer Cell. 2012;21:723–737.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells. Clin Cancer Res. 2008;14:4650–4657.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Advances. 2018;2:1595–1607.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hwang J, Mannis G. Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL. Hematol Oncol. 2017;35:343–344.
   Google Scholar
• Tsang M, Cleveland J, Cerejo MC, et al. Survival and patient-reported outcomes of older adults with primary central nervous system lymphoma on low-dose lenalidomide. Blood. 2020 Internet;136:21–22.
   Google Scholar
• Rubenstein JL, Fraser E, Formaker P, et al. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. J Clin Oncol. 2016 Internet;34:7502.
   Google Scholar
• Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) network and. Ann Oncol. 2019 Internet;30:621–628.
   PubMed Web of Science ®Google Scholar
• Ma J, Chen B, Zhiguang L, et al. Efficacy and safety of pemetrexed combined with lenalidomide in the treatment of relapsed/refractory primary central nervous system lymphoma. Blood. 2020 Internet;136:2–3.
   Google Scholar
• Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018 Internet;132:2240–2248.
   PubMed Web of Science ®Google Scholar
• Grommes C, Piotrowski A, Pentsova E, et al. Phase Ib ansion of the Bruton’s Tyrosine Kinase (BTK) inhibitor, Ibrutinib, in combination with rituximab and lenalidomide in patients with refractory/recurrent Primary Central Nervous System Lymphoma (PCNSL) and refractory/recurrent se. Blood. 2020 [Internet];136:48.
   Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;3071–3073.Internet.
   PubMedGoogle Scholar
• Hoang-Xuan K, Houot R, Soussain C, et al. First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort. Blood. 2020 Internet;136:15–16.
   Google Scholar
• Kuhn JG, Chang SM, Wen PY, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13:7401–7406.
   PubMed Web of Science ®Google Scholar
• Korfel A, Schlegel U, Herrlinger U, et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma. J Clin Oncol. 2016 Internet;34:1757–1763.
   PubMedGoogle Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma. N Engl J Med. 2019;380:45–56.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–852.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134:860–866.
   PubMed Web of Science ®Google Scholar
• Li T, Zhao L, Zhang Y, et al. CAR T-cell therapy is effective but not long-lasting in B-cell lymphoma of the brain. Front Oncol. 2020;10:1306.
   PubMedGoogle Scholar
• Alcantara M, Houillier C, Le Garff-Tavernier M, et al. CAR-T cell therapy in primary central nervous system lymphoma (pcnsl): the experience of the french network for Oculo-Cerebral Lymphomas (LOC). Blood. 2022;139:792–796.
   PubMedGoogle Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary cns lymphoma. Cancer Cell. 2017;31:833–843.e5.
   PubMed Web of Science ®Google Scholar
• Siddiqi T, Xiuli Wang MSB, Wagner JR, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021;5:4059–4063.
   PubMed Web of Science ®Google Scholar